<DOC>
	<DOC>NCT00383513</DOC>
	<brief_summary>Epratuzumab is an investigational antibody designed to help treat Systemic Lupus Erythematosus (SLE). The purpose of the study is to obtain additional long-term information regarding the safety and efficacy of continued maintenance-cycle administrations of Epratuzumab.</brief_summary>
	<brief_title>Study of Epratuzumab in Systemic Lupus Erythematosus</brief_title>
	<detailed_description>Due to the logistical considerations, UCB has decided to consolidate the Phase II and Phase III open-label extension trials. Subjects completing this study will be offered the option of continuing to receive epratuzumab through participation in Phase III open-label extension study SL0012 (NCT01408576).</detailed_description>
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Must have participated in SL0003 or SL0004 and benefitted from participation in those studies Development of toxicity to epratuzumab Significant protocol deviations during the SL0003 or SL0004 studies Evidence of significant infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Antibody</keyword>
	<keyword>B-Cell Immunotherapy</keyword>
</DOC>